blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3052655

EP3052655 - CLOSANTEL IN COMBINATION WITH TEMOZOLOMIDE FOR USE IN THE TREATMENT OF A CANCER IN WHICH IS THYMINE DNA GLYCOSYLASE EXPRESSED [Right-click to bookmark this link]
Former [2016/32]INHIBITION OF THYMINE DNA GLYCOSYLASE IN THE TREATMENT OF CANCER
[2018/21]
StatusNo opposition filed within time limit
Status updated on  13.09.2019
Database last updated on 13.11.2024
FormerThe patent has been granted
Status updated on  05.10.2018
FormerGrant of patent is intended
Status updated on  23.05.2018
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Institute For Cancer Research D/b/a The Research Institute of Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111-2497 / US
For all designated states
Institut de Génétique et de Biologie Moléculaire et Cellulaire
1, rue Laurent Fries
BP 10142
67404 Illkrich / FR
For all designated states
Institut Curie
26, rue d'Ulm
75248 Paris Cedex 05 / FR
[2016/32]
Inventor(s)01 / BELLACOSA, Alfonso
333 Cottman Avenue
Philadelphia, PA 19111-2497 / US
02 / TRICARICO, Rossella
333 Cottman Avenue
Philadelphia, PA 19111-2497 / US
03 / YEN, Tim
333 Cottman Avenue
Philadelphia, PA 19111-2497 / US
04 / BHATTACHARJEE, Vikram
333 Cottman Avenue
Philadelphia, PA 19111-2497 / US
05 / MANCUSO, Pietro
333 Cottman Avenue
Philadelphia, PA 19111-2497 / US
06 / LARUE, Lionel
Institut Curie
26 rue D'Ulm
75248 Paris / FR
07 / DAVIDSON, Irwin
IGBMC
1 Rue Laurent Fries
BP 10142
67404 Illkrich / FR
 [2018/25]
Former [2016/32]01 / BELLACOSA, Alfonso
333 Cottman Avenue
Philadelphia, PA 19111-2497 / US
02 / TRICARICO, Rossella
333 Cottman Avenue
Philadelphia, PA 19111-2497 / US
03 / YEN, Tim
333 Cottman Avenue
Philadelphia, PA 19111-2497 / US
04 / BHATTACHARJEE, Vikram
333 Cottman Avenue
Philadelphia, PA 19111-2497 / US
05 / MANCUSO, Pietro
333 Cottman Avenue
Philadelphia, PA 19111-2497 / US
06 / LARUE, Lionel
Institut Curie
26 rue D'Ulm
F-75248 Paris / FR
07 / DAVIDSON, Irwin
IGBMC
1 Rue Laurent Fries
BP 10142
F-67404 Illkrich / FR
Representative(s)Ghirardi, Valeria, et al
Cantaluppi & Partners S.r.l.
Via Strobel, 8
20133 Milano / IT
[N/P]
Former [2018/45]Spadaro, Marco, et al
Cantaluppi & Partners S.r.l.
Via Strobel, 8
20133 Milano / IT
Former [2016/32]Spadaro, Marco, et al
Cantaluppi & Partners
Via Pellegrino Strobel
20133 Milano / IT
Application number, filing date14847598.130.09.2014
[2016/32]
WO2014US58240
Priority number, dateUS201361884478P30.09.2013         Original published format: US 201361884478 P
[2016/32]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2015048718
Date:02.04.2015
Language:EN
[2015/13]
Type: A2 Application without search report 
No.:EP3052655
Date:10.08.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 02.04.2015 takes the place of the publication of the European patent application.
[2016/32]
Type: B1 Patent specification 
No.:EP3052655
Date:07.11.2018
Language:EN
[2018/45]
Search report(s)International search report - published on:US18.06.2015
(Supplementary) European search report - dispatched on:EP01.03.2017
ClassificationIPC:A61K31/277, A61K31/495, A61P35/00
[2018/21]
CPC:
A61K31/5575 (EP,US); A61K31/122 (EP,US); A61K31/277 (US);
A61K31/353 (EP,US); A61K31/404 (EP,US); A61K31/473 (EP,US);
A61K31/475 (US); A61K31/495 (US); A61K31/546 (EP,US);
A61K31/609 (EP,US); A61K33/24 (US); A61K33/243 (EP,US);
A61P35/00 (EP,US); C12N2740/15043 (EP,US) (-)
Former IPC [2016/32]C12Q1/68
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/32]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:CLOSANTEL IN KOMBINATION MIT TEMOZOLOMID ZUR BEHANDLUNG VON THYMIN DNA GLYKOSYLASE EXPRIMIERENDEM KREBS[2018/21]
English:CLOSANTEL IN COMBINATION WITH TEMOZOLOMIDE FOR USE IN THE TREATMENT OF A CANCER IN WHICH IS THYMINE DNA GLYCOSYLASE EXPRESSED[2018/21]
French:CLOSANTEL EN COMBINAISON AVEC TEMOZOLOMIDE POUR LE TRAITEMENT D'UN CANCER EXPRIMANT LA THYMINE DNA GLYCOSYLASE[2018/21]
Former [2016/32]HEMMUNG VON THYMIN-DNA-GLYCOSYLASE BEI DER BEHANDLUNG VON KREBS
Former [2016/32]INHIBITION OF THYMINE DNA GLYCOSYLASE IN THE TREATMENT OF CANCER
Former [2016/32]INHIBITION DE LA THYMINE DNA GLYCOSYLASE DANS LE TRAITEMENT DU CANCER
Entry into regional phase31.03.2016National basic fee paid 
31.03.2016Search fee paid 
31.03.2016Designation fee(s) paid 
31.03.2016Examination fee paid 
Examination procedure31.03.2016Examination requested  [2016/32]
21.09.2017Amendment by applicant (claims and/or description)
24.05.2018Communication of intention to grant the patent
20.09.2018Fee for grant paid
20.09.2018Fee for publishing/printing paid
20.09.2018Receipt of the translation of the claim(s)
Opposition(s)08.08.2019No opposition filed within time limit [2019/42]
Fees paidRenewal fee
27.09.2016Renewal fee patent year 03
27.09.2017Renewal fee patent year 04
27.09.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.09.2014
AL07.11.2018
AT07.11.2018
CY07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
ES07.11.2018
FI07.11.2018
HR07.11.2018
LT07.11.2018
LV07.11.2018
MC07.11.2018
MK07.11.2018
MT07.11.2018
NL07.11.2018
PL07.11.2018
RO07.11.2018
RS07.11.2018
SE07.11.2018
SI07.11.2018
SK07.11.2018
SM07.11.2018
TR07.11.2018
BG07.02.2019
NO07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
[2022/31]
Former [2021/34]HU30.09.2014
AL07.11.2018
AT07.11.2018
CY07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
ES07.11.2018
FI07.11.2018
HR07.11.2018
LT07.11.2018
LV07.11.2018
MC07.11.2018
MT07.11.2018
NL07.11.2018
PL07.11.2018
RO07.11.2018
RS07.11.2018
SE07.11.2018
SI07.11.2018
SK07.11.2018
SM07.11.2018
TR07.11.2018
BG07.02.2019
NO07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2021/32]HU30.09.2014
AL07.11.2018
AT07.11.2018
CY07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
ES07.11.2018
FI07.11.2018
HR07.11.2018
LT07.11.2018
LV07.11.2018
MC07.11.2018
NL07.11.2018
PL07.11.2018
RO07.11.2018
RS07.11.2018
SE07.11.2018
SI07.11.2018
SK07.11.2018
SM07.11.2018
TR07.11.2018
BG07.02.2019
NO07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2021/26]AL07.11.2018
AT07.11.2018
CY07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
ES07.11.2018
FI07.11.2018
HR07.11.2018
LT07.11.2018
LV07.11.2018
MC07.11.2018
NL07.11.2018
PL07.11.2018
RO07.11.2018
RS07.11.2018
SE07.11.2018
SI07.11.2018
SK07.11.2018
SM07.11.2018
TR07.11.2018
BG07.02.2019
NO07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2020/25]AL07.11.2018
AT07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
ES07.11.2018
FI07.11.2018
HR07.11.2018
LT07.11.2018
LV07.11.2018
MC07.11.2018
NL07.11.2018
PL07.11.2018
RO07.11.2018
RS07.11.2018
SE07.11.2018
SI07.11.2018
SK07.11.2018
SM07.11.2018
TR07.11.2018
BG07.02.2019
NO07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2020/17]AL07.11.2018
AT07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
ES07.11.2018
FI07.11.2018
HR07.11.2018
LT07.11.2018
LV07.11.2018
NL07.11.2018
PL07.11.2018
RO07.11.2018
RS07.11.2018
SE07.11.2018
SI07.11.2018
SK07.11.2018
SM07.11.2018
TR07.11.2018
BG07.02.2019
NO07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2019/50]AL07.11.2018
AT07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
ES07.11.2018
FI07.11.2018
HR07.11.2018
LT07.11.2018
LV07.11.2018
NL07.11.2018
PL07.11.2018
RO07.11.2018
RS07.11.2018
SE07.11.2018
SI07.11.2018
SK07.11.2018
SM07.11.2018
BG07.02.2019
NO07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2019/40]AL07.11.2018
AT07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
ES07.11.2018
FI07.11.2018
HR07.11.2018
LT07.11.2018
LV07.11.2018
NL07.11.2018
PL07.11.2018
RO07.11.2018
RS07.11.2018
SE07.11.2018
SK07.11.2018
SM07.11.2018
BG07.02.2019
NO07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2019/37]AL07.11.2018
AT07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
ES07.11.2018
FI07.11.2018
HR07.11.2018
LT07.11.2018
LV07.11.2018
NL07.11.2018
PL07.11.2018
RO07.11.2018
RS07.11.2018
SE07.11.2018
SM07.11.2018
BG07.02.2019
NO07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2019/35]AL07.11.2018
AT07.11.2018
CZ07.11.2018
DK07.11.2018
ES07.11.2018
FI07.11.2018
HR07.11.2018
LT07.11.2018
LV07.11.2018
NL07.11.2018
PL07.11.2018
RS07.11.2018
SE07.11.2018
BG07.02.2019
NO07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2019/34]AL07.11.2018
AT07.11.2018
DK07.11.2018
ES07.11.2018
FI07.11.2018
HR07.11.2018
LT07.11.2018
LV07.11.2018
NL07.11.2018
RS07.11.2018
SE07.11.2018
BG07.02.2019
NO07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2019/26]AL07.11.2018
AT07.11.2018
ES07.11.2018
FI07.11.2018
HR07.11.2018
LT07.11.2018
LV07.11.2018
NL07.11.2018
RS07.11.2018
SE07.11.2018
BG07.02.2019
NO07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2019/25]AT07.11.2018
ES07.11.2018
FI07.11.2018
HR07.11.2018
LT07.11.2018
LV07.11.2018
NL07.11.2018
RS07.11.2018
SE07.11.2018
BG07.02.2019
NO07.02.2019
GR08.02.2019
IS07.03.2019
Former [2019/24]AT07.11.2018
ES07.11.2018
FI07.11.2018
HR07.11.2018
LT07.11.2018
LV07.11.2018
NL07.11.2018
SE07.11.2018
BG07.02.2019
NO07.02.2019
GR08.02.2019
IS07.03.2019
Former [2019/23]AT07.11.2018
ES07.11.2018
FI07.11.2018
HR07.11.2018
LT07.11.2018
LV07.11.2018
NL07.11.2018
BG07.02.2019
NO07.02.2019
IS07.03.2019
Former [2019/22]FI07.11.2018
LT07.11.2018
BG07.02.2019
NO07.02.2019
IS07.03.2019
Former [2019/21]FI07.11.2018
LT07.11.2018
NO07.02.2019
IS07.03.2019
Former [2019/20]LT07.11.2018
NO07.02.2019
Documents cited:Search[Y]WO2011130429  (MAYO FOUNDATION [US], et al) [Y] 1-3,10-12* claim 4 *;
 [AP]US2013303588  (BELLACOSA ALFONSO [US], et al) [AP] 1,2,4 * paragraphs [0060] , [0062] , [0064] , [0066]; example 10; claims 1,4,6,7,9; sequence 2 *;
 [AP]  - X. XU ET AL, "Thymine DNA Glycosylase Is a Positive Regulator of Wnt Signaling in Colorectal Cancer", JOURNAL OF BIOLOGICAL CHEMISTRY, US, (20140328), vol. 289, no. 13, doi:10.1074/jbc.M113.538835, ISSN 0021-9258, pages 8881 - 8890, XP055295659 [AP] 1,2,4 * page 8882 *

DOI:   http://dx.doi.org/10.1074/jbc.M113.538835
 [Y]  - AWADA A ET AL, "Prolonged schedule of temozolomide (Temodal) plus liposmal doxorubicin (Caelyx) in advanced solid cancers", ANTI-CANCER DRUGS, (200406), vol. 15, no. 5, ISSN 0959-4973, pages 499 - 502, XP009191386 [Y] 1-3,10-12 * page 499 *
 [X]  - K. B. AITHAL ET AL, "Tumor Growth Inhibitory Effect of Juglone and Its Radiation Sensitizing Potential: In Vivo and In Vitro Studies", INTEGRATIVE CANCER THERAPIES, US, (20120301), vol. 11, no. 1, doi:10.1177/1534735411403477, ISSN 1534-7354, pages 68 - 80, XP055295697 [X] 1,2,4 * page 70 *

DOI:   http://dx.doi.org/10.1177/1534735411403477
 [X]  - KIRAN AITHAL B ET AL, "Juglone, a naphthoquinone from walnut, exerts cytotoxic and genotoxic effects against cultured melanoma tumor cells", CELL BIOLOGY INTERNATIONAL, ACADEMIC PRESS, GB, vol. 33, no. 10, doi:10.1016/J.CELLBI.2009.06.018, ISSN 1065-6995, (20091001), pages 1039 - 1049, (20090623), XP026574483 [X] 1,2,4 * page 1040 *

DOI:   http://dx.doi.org/10.1016/j.cellbi.2009.06.018
 [X]  - JI Y B ET AL, "Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway", EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, JENA, DE, vol. 63, no. 1-2, ISSN 0940-2993, (20110101), pages 69 - 78, (20091007), XP027561270 [X] 1,2,4 * page 70 *
 [X]  - ZHANG WEI ET AL, "Anticancer activity and mechanism of juglone on human cervical carcinoma HeLa cells", CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, (201211), vol. 90, no. 11, pages 1553 - 1558, XP009191387 [X] 1,2,4 * page 1554 *
 [I]  - MONTENEGRO R C ET AL, "Cytotoxic activity of naphthoquinones with special emphasis on juglone and its 5-O-methyl derivative", CHEMICO-BIOLOGICAL INTERACTIONS, ELSEVIER SCIENCE IRLAND, IR, vol. 184, no. 3, ISSN 0009-2797, (20100330), pages 439 - 448, (20100204), XP026982207 [I] 1,2,4 * page 441 *
 [X]  - AITHAL B KIRAN ET AL, "Evaluation of pharmacokinetic, biodistribution, pharmacodynamic, and toxicity profile of free juglone and its sterically stabilized liposomes.", JOURNAL OF PHARMACEUTICAL SCIENCES AUG 2011, (201108), vol. 100, no. 8, ISSN 1520-6017, pages 3517 - 3528, XP009191390 [X] 1,2,4 * page 3518 *
 [X]  - KUMAR M R S ET AL, "Cytotoxic, genotoxic and oxidative stress induced by 1,4-naphthoquinone in B16F1 melanoma tumor cells", TOXICOLOGY IN VITRO, ELSEVIER SCIENCE, GB, vol. 23, no. 2, doi:10.1016/J.TIV.2008.12.004, ISSN 0887-2333, (20090301), pages 242 - 250, (20081214), XP025913306 [X] 1,2,4 * page 243 *

DOI:   http://dx.doi.org/10.1016/j.tiv.2008.12.004
 [IY]  - LARS M. WAGNER ET AL, "Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study", PEDIATRIC BLOOD AND CANCER, US, (20100104), vol. 54, doi:10.1002/pbc.22407, ISSN 1545-5009, pages 538 - 545, XP055341469 [I] 1-3,10-12 * page 539 * [Y] 1-3,10-12

DOI:   http://dx.doi.org/10.1002/pbc.22407
 [XYI]  - LARS WAGNER ET AL, "Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors", PEDIATRIC BLOOD AND CANCER, US, (20130929), vol. 60, no. 9, doi:10.1002/pbc.24547, ISSN 1545-5009, pages 1447 - 1451, XP055341496 [X] 1-3,10-12 * page 1448 * [Y] 1-3,10-12 [I] 4-9,13-15

DOI:   http://dx.doi.org/10.1002/pbc.24547
 [A]  - P H COTTU ET AL, "High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study", BRITISH JOURNAL OF CANCER, GB, (20011102), vol. 85, no. 9, doi:10.1054/bjoc.2001.2069, ISSN 0007-0920, pages 1240 - 1246, XP055341566 [A] 1-15 * page 1241 *

DOI:   http://dx.doi.org/10.1054/bjoc.2001.2069
 [A]  - MOOK ROBERT A ET AL, "Small molecule modulators of Wnt/[beta]-catenin signaling", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, (20130130), vol. 23, no. 7, doi:10.1016/J.BMCL.2013.01.101, ISSN 0960-894X, pages 2187 - 2191, XP028997371 [A] 1-15 * page 2188 *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2013.01.101
 [Y]  - KEIICHI TOZAWA ET AL, "Gold compounds inhibit adhesion of human cancer cells to vascular endothelial cells", CANCER LETTERS, US, (20030601), vol. 196, no. 1, doi:10.1016/S0304-3835(03)00149-6, ISSN 0304-3835, pages 93 - 100, XP055341595 [Y] 1-3,10-12 * page 95 *

DOI:   http://dx.doi.org/10.1016/S0304-3835(03)00149-6
 [Y]  - STAILINGS-MANN M ET AL, "A novel small-molecule inhibitor of protein kinase C[iota] blocks transformed growth of non-small-cell lung cancer cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, (20060201), vol. 66, no. 3, doi:10.1158/0008-5472.CAN-05-3405, ISSN 0008-5472, pages 1767 - 1774, XP002545934 [Y] 1-3,10-12 * page 1768 *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-05-3405
International search[X]US2009062196  (D ANDREA ALAN [US], et al);
 [Y]US8268352  (VAYA NAVIN [IN], et al);
 [Y]US2013244920  (LEE DAVID M [US], et al);
 [Y]  - MOHAN, RD ET AL., "Mus musculus thymine DNA glycosylase (Tdg", GENBANK, (20070903), Database accession no. NM_011561, URL: NCBI, XP055273663
 [Y]  - ICTIDOMYS TRIDECEMLINEATUS., "PREDICTED: ICTIDOMYS TRIDECEMLINEATUS THYMINE DNA GLYCOSYLASE (TDG), TRANSCRIPT VARIANT X2, MRNA", GENBANK, (20130821), Database accession no. XM_005322345, URL: NCBI, XP055273719
by applicantCA78412
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.